Non-Profit Partners Fact Sheet

Between 2002–2011, the ATS and its non-profit partners co-sponsored 76 research grants, investing $4,505,000 towards a future free from lung disease.

Who are our non-profit partners?
Our non-profit partners include patient advocacy and family foundations, both in the United States and abroad. Many of our non-profit partners are members of ATS Patient Advocacy Roundtable (Patients.thoracic.org). Our non-profit partners provide a patient voice that helps direct funding to research projects that will have the greatest impact on improving patient quality of life.

Maximizing Financial Resources
The ATS Foundation grants provide $80,000 over 2 years ($40,000/year) in research support. The ATS Foundation pools its financial resources with that of its non-profit partners to maximize the number of available research grants. Specifically, the Foundation provides $20,000 towards each grant and assumes the responsibility of advertising, reviewing, and administering awards. Our partners determine the type of research we support and develop a call for applications.

For non-profit groups who are unable to independently contribute $60,000 towards a research grant, the ATS Foundation facilitates partnerships among groups with similar clinical interests to help raise the necessary funds. In addition, the Foundation also fosters collaborations between non-profits and industry to maximize funding. This is exemplified in the ATS/Pfizer/Pulmonary Hypertension Association partnership, which has produced four awards in pulmonary arterial hypertension research since 2010.

Grant Review
The ATS Foundation and its partners fund research proposals that present the most innovative scientific ideas and that hold the best potential to address patient needs.

- ATS SAC: The ATS Scientific Advisory Committee reviews all grant applications in a rigorous NIH-style review process.
- Patient Review: Beginning in 2012, non-profit partners will select patient advocates to represent the patient voice during the scientific review process.

Furthering Scientific Discovery: In addition to strengthening existing partnerships, we are currently seeking partners interested in co-funding awards in the following areas:

- Environmental triggers of lung disease
- Lymphangiomatosis & Gorham’s Disease
- Diversity among researchers
- Occupational triggers of lung disease
- Lung Cancer
- Primary Ciliary Dyskinesia

Thank you for your support of our Research Program!

Alpha-1 Foundation
American Lung Association
American Lung Association of Hawaii
American Lung Association of Oregon
American Society of Transplantation
ATS Foundation Tobacco-Dependence Research Fund
ARDS Foundation
Asthma and Allergy Foundation of America
Boehringer Ingelheim Pharmaceuticals, Inc.

chILD Foundation
chILD (Lung) Foundation-UK
Coalition for Pulmonary Fibrosis
Emphysema Fight for Our Right to Survive Foundation for Sarcoidosis Research
Hermansky-Pudlak Syndrome Network
The LAM Foundation
LAM Treatment Alliance
LUNGevity Foundation
Merck

The Nathan Cummings Foundation
Pfizer, Inc.
Pulmonary Fibrosis Foundation
Pulmonary Hypertension Association
Respiratory Health Association of Metropolitan Chicago
Respirorics Foundation
Sarcoidosis Research Institute
Sepsis Alliance
Veterans Administration